Is there a best timing for benign prostatic hyperplasia surgery?
5 alpha-reductase inhibitors
Alpha-blocker
Benign prostatic hyperplasia
Green light
Holep
Laser
Lower urinary tract symptoms
Transurethral resection of the prostate
Journal
The French journal of urology
ISSN: 2950-3930
Titre abrégé: Fr J Urol
Pays: France
ID NLM: 9918752079106676
Informations de publication
Date de publication:
Mar 2024
Mar 2024
Historique:
received:
17
03
2023
revised:
12
06
2023
accepted:
26
10
2023
medline:
8
5
2024
pubmed:
8
5
2024
entrez:
8
5
2024
Statut:
ppublish
Résumé
Treatment of lower urinary tract symptoms (LUTS) related to benign prostatic hyperplasia (BPH) has shifted over the last decades, with medical therapy becoming the primary treatment modality while surgery is being reserved mostly to patients who are not responding to medical treatment or presenting with complications from BPH. Here, we aim to to discuss the optimal timing of surgical management of LUTS/BPH. A literature search was conducted on Pub-Med/MEDLINE database to identify reports published from January 1990 until January 2022 by combining the following MeSH terms: "Lower Urinary Tract Symptoms"; "Prostatic Hyperplasia"; "Prostatic Hyperplasia/therapy"; "Prostatic Hyperplasia/complications"; "Treatment Outcome"; "Time-to-Treatment". Evidence supporting or not early surgical treatment of BPH was examined and reported in a pros and cons form. The "pro early surgery" highlighted the superior efficacy and cost-effectiveness of surgery over medical treatment for BPH, as well as the possibility of worse postoperative outcomes for delayed surgical treatment. The "con early surgery" considered that medical therapy is efficient in well-selected patients and can avoid the serious risks inherent to surgical treatment of BPH including important sexual side effects. Clinical trials comparing the outcomes for prolonged medical therapy versus early surgical treatment could determine which approach is more beneficial in the long-term in context of the aging population. Until then, both approaches have their advantages and patients should be involved in the treatment decision.
Identifiants
pubmed: 38717461
pii: S2950-3930(24)00008-1
doi: 10.1016/j.fjurol.2024.102574
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102574Informations de copyright
Copyright © 2024 Elsevier Masson SAS. All rights reserved.